Clinical Trial Update: Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab with or without ipilimumab in metastatic or unresectable gastrointestinal stromal tumor (GIST).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Gastrointestinal Stromal Tumor | Phase 2 | Status: COMPLETED